Potential and limits of cannabinoids in Alzheimer's disease therapy

G Abate, D Uberti, S Tambaro - Biology, 2021 - mdpi.com
Simple Summary This review was aimed at exploring the potentiality of drugging the
endocannabinoid system as a therapeutic option for Alzheimer's disease (AD). Recent …

Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic

E Aso, I Ferrer - Frontiers in pharmacology, 2014 - frontiersin.org
The limited effectiveness of current therapies against Alzheimer's disease (AD) highlights
the need for intensifying research efforts devoted to developing new agents for preventing or …

Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer's disease

M Coles, GZ Steiner-Lim, T Karl - Frontiers in Neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is a debilitating neurodegenerative disease characterized by
declining cognition and behavioral impairment, and hallmarked by extracellular amyloid-β …

The therapeutic potential of the endocannabinoid system for Alzheimer's disease

T Karl, D Cheng, B Garner, JC Arnold - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Dementia currently affects over 35 million people worldwide. The most common
form of dementia is Alzheimer's disease (AD). Currently, treatments for AD do not stop or …

[HTML][HTML] Cannabis sativa and cannabidiol: a therapeutic strategy for the treatment of neurodegenerative diseases?

MB Viana, PEA Aquino, D Estadella… - Medical Cannabis and …, 2022 - karger.com
This work is a literature review, presenting the current state of the use of cannabinoids on
neurodegenerative diseases. The emphasis is on Parkinson's (PD) and Alzheimer's (AD) …

The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease

T Karl, B Garner, D Cheng - Behavioural pharmacology, 2017 - journals.lww.com
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by
progressive loss of cognition. Over 35 million individuals currently have AD worldwide …

Recent advances in the potential of cannabinoids for neuroprotection in Alzheimer's, Parkinson's, and Huntington's diseases

C Pérez-Olives, R Rivas-Santisteban, J Lillo… - Cannabinoids and …, 2020 - Springer
Three prevalent neurodegenerative diseases, Parkinson's, Alzheimer's, and Huntington's
are in need of symptomatic relief of slowing disease progression or both. This chapter …

Emerging promise of cannabinoids for the management of pain and associated neuropathological alterations in Alzheimer's disease

MS Uddin, AA Mamun, DM Sumsuzzman… - Frontiers in …, 2020 - frontiersin.org
Alzheimer's disease (AD) is an irreversible chronic neurodegenerative disorder that occurs
when neurons in the brain degenerate and die. Pain frequently arises in older patients with …

Cannabinoids in late‐onset Alzheimer's disease

AIA Ahmed, MA Van Der Marck… - Clinical …, 2015 - Wiley Online Library
Given the lack of effective treatments for late‐onset Alzheimer's disease (LOAD) and the
substantial burden on patients, families, health care systems, and economies, finding an …

[HTML][HTML] Phytocannabinoids and cannabis-based products as alternative pharmacotherapy in neurodegenerative diseases: From hypothesis to clinical practice

Y Paes-Colli, AFL Aguiar, AR Isaac… - Frontiers in cellular …, 2022 - frontiersin.org
Historically, Cannabis is one of the first plants to be domesticated and used in medicine,
though only in the last years the amount of Cannabis-based products or medicines has …